^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

PGR negative

i
Entrez ID:
Related biomarkers:
3d
Association of the SNPs in CCL2 and CXCL12 genes with the susceptibility to breast cancer: a case-control study in China. (PubMed, Front Oncol)
CCL2 and CXCL12 SNPs are associated with breast cancer susceptibility in overweight and postmenopausal women, and the effect varies according to subtypes. The interaction of SNPs within CXCL12 gene and the association with breast cancer survival further suggest potential targets for improved risk assessment and treatment strategies.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CCL2 (Chemokine (C-C motif) ligand 2)
|
HER-2 positive • ER negative • PGR negative
5d
Anti‑proliferative effects of Drynaria fortunei in a model for triple negative breast cancer. (PubMed, Oncol Lett)
It is typically responsive to anthracycline/taxol-based conventional chemotherapy...These data identify potential mechanistic leads for anti-proliferative and pro-apoptotic effects of DF in the present TNBC model. The present experiments validated a mechanism-driven experimental approach to identify efficacious nutritional herbs and/or their bioactive constituents as treatment alternatives for TNBC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CDK4 (Cyclin-dependent kinase 4) • CASP3 (Caspase 3) • CDK2 (Cyclin-dependent kinase 2) • CASP7 (Caspase 7) • E2F1 (E2F transcription factor 1)
|
HER-2 negative • ER negative • PARP1 expression • PGR negative • CDK2 expression
|
paclitaxel
10d
Association between long-term ambient air pollution exposure and the incidence of breast cancer: A meta-analysis based on updated evidence. (PubMed, Ecotoxicol Environ Saf)
This study is the first to document a significant association between long-term exposure to ambient PM2.5 and breast cancer incidence through meta-analysis. Air pollution has a pronounced impact on postmenopausal breast cancer, and the strength of the association between specific air pollutants and breast cancer incidence varies across regions. These findings suggest that long-term exposure to NO2 and PM2.5 may increase the incidence of breast cancer.
Retrospective data • Review • Journal
|
PGR (Progesterone receptor)
|
ER positive + PGR positive • PGR positive • PGR negative
11d
OptiTROP-Breast01: SKB264 Injection Vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
P3, N=254, Active, not recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Trial completion date: Dec 2024 --> Mar 2025
Trial completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA2 mutation • BRCA1 mutation • HER-2 negative • HER-2 expression • PGR negative • HER-2 negative + HR positive + BRCA mutation
|
gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • sacituzumab tirumotecan (MK-2870)
13d
FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer (clinicaltrials.gov)
P2, N=21, Active, not recruiting, University of Wisconsin, Madison | Recruiting --> Active, not recruiting
Enrollment closed
|
PGR (Progesterone receptor)
|
PGR negative
19d
Decrescendo: De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade (clinicaltrials.gov)
P2, N=139, Terminated, Jules Bordet Institute | N=1065 --> 139 | Trial completion date: Mar 2029 --> Nov 2024 | Suspended --> Terminated | Trial primary completion date: Jun 2027 --> Nov 2024; Serious concerns on the slow recruitment of the study that impacts the robustness of the scientific rationale and the study financial provision. It aims to assess carefully the situation and to evaluate the potential solutions to overcome the issues.
Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER negative • PGR negative
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
|
Kadcyla (ado-trastuzumab emtansine) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
19d
Loss of ERα involved-HER2 induction mediated by the FOXO3a signaling pathway in fulvestrant-resistant breast cancer. (PubMed, Biochem Biophys Res Commun)
These results suggest that the suppression of FOXO3a and ERα led to the increased expression of TGF-α, EGFR, and HER2 and subsequent cell proliferation in Ful-R. This study highlights the potential development of therapeutic drugs targeting FOXO3a for the treatment of HER2-positive, estrogen, and progesterone receptor-negative her2-type proliferative breast cancers.
Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • HER-2 expression • PGR negative
|
fulvestrant
20d
Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PGR negative
1m
A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC (clinicaltrials.gov)
P2, N=9, Terminated, Chipscreen Biosciences, Ltd. | N=38 --> 9 | Recruiting --> Terminated; During the enrollment period of this project, due to the increasing proportion of patients receiving capecitabine adjuvant therapy and the large number of trials competing for the same number of lines in various centers
Enrollment change • Trial termination • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER negative • PGR negative
|
capecitabine • chiauranib (CS 2164)
1m
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers (clinicaltrials.gov)
P1/2, N=26, Completed, Sellas Life Sciences Group | Active, not recruiting --> Completed | N=90 --> 26
Trial completion • Enrollment change • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • PGR (Progesterone receptor) • WT1 (WT1 Transcription Factor) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
|
HER-2 negative • KRAS wild-type • RAS wild-type • BRCA mutation • PGR negative
|
Keytruda (pembrolizumab) • Zeltherva (galinpepimut-S) • Leukine (sargramostim)
1m
CASE6119: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer (clinicaltrials.gov)
P1, N=45, Recruiting, George T. Budd | Trial completion date: Mar 2025 --> Nov 2025 | Trial primary completion date: Nov 2024 --> May 2025
Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • PRL (Prolactin)
|
BRCA1 mutation • HER-2 negative • PALB2 mutation • ER negative • PGR negative
|
alpha-lactalbumin vaccine
1m
Analyzing Androgen Receptor Expression in Breast Cancer: Insights into Histopathological Parameters and Hormone Receptor Status Among Indian Women. (PubMed, Indian J Surg Oncol)
AR emerges as a promising marker in breast cancers, particularly in triple-negative cases. Larger-scale studies are warranted to comprehensively assess the relationship between AR expression and histopathological parameters, as well as other immunohistochemical markers.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor)
|
HER-2 overexpression • AR positive • AR expression • AR negative • PGR expression • PGR negative
1m
Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HR positive • HER-2 negative • EGFR positive • PGR negative
|
MammaPrint
1m
A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol (clinicaltrials.gov)
P2, N=220, Active, not recruiting, West German Study Group | Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Jan 2025 | Trial primary completion date: Aug 2015 --> Jan 2025
Enrollment closed • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
PGR negative
|
Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab)
1m
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative • PGR negative
|
Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
2ms
Systemic hormone therapy after breast and gynecological cancers: an Italian expert group consensus opinion. (PubMed, Climacteric)
ET/HT can probably be used after ovarian neoplasms except for granulosa cell tumors, and with great caution after low-grade serous ovarian carcinoma and serous borderline ovarian tumors. ET/HT can be used with great caution in women after estrogen receptor (ER)/progesterone receptor (PR)-positive breast cancer and is probably allowed after ER/PR-negative breast cancer.
Review • Journal
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER negative • PGR negative
2ms
GO39733: A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors (clinicaltrials.gov)
P1, N=272, Active, not recruiting, Genentech, Inc. | Trial completion date: Nov 2024 --> Mar 2025 | Trial primary completion date: Nov 2024 --> Mar 2025
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PGR negative
|
Tecentriq (atezolizumab) • autogene cevumeran (RG6180)
2ms
Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
PD-L1 expression • HER-2 negative • ER negative • PGR negative
|
VENTANA PD-L1 (SP142) Assay
|
Tecentriq (atezolizumab) • carboplatin • paclitaxel • cyclophosphamide • epirubicin
2ms
The role of adjuvant endocrine treatment in ER+, PR-, HER2- early breast cancer: a retrospective study of real-world data. (PubMed, Sci Rep)
ER+/PR-/HER2- BC was a special subtype with aggressive clinicopathological features and more tend to have distant metastasis rather than nodal involvement or local relapse. ER+/PR-/HER2- early BC did not seem to benefit from adjuvant ET.
Retrospective data • Journal • Real-world evidence • Real-world
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR negative
2ms
PR status cannot predict Oncotype DX Recurrence Score®: a study in a Greek cohort of N0M0/ER+/PR-/HER2- breast cancer patients tested with Oncotype DX (SABCS 2024)
In PR-negative, pT1-3N0, cM0/ER+/HER2- breast cancer patients, PR status alone does not predict the RS and hence, the benefit of chemotherapy. The Oncotype DX assay effectively stratifies these patients, highlighting those with high RS (>25) who will benefit from chemotherapy. These findings underscore the importance of using Oncotype DX scores rather than PR status alone to guide chemotherapy decisions in PR-negative breast cancer patients.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 negative • PGR negative
|
Oncotype DX Breast Recurrence Score®Test
2ms
Effectiveness of Predictive Calculators for Breast Cancer Recurrence: A Comparative Study with the 21-Gene Score (SABCS 2024)
Only the established Johns Hopkins University calculator demonstrated good performance in correctly stratifying our patients. This highlights the need for further refinement and validation in predictive models across diverse patient populations to optimize medical decisions.
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HR positive • HER-2 negative • PGR positive • PGR negative • HER-2 negative + PGR positive
|
Oncotype DX Breast Recurrence Score®Test
2ms
A case of sequential alpelisib and capivasertib in a patient with metastatic breast cancer harboring both a PIK3CA and AKT mutations (SABCS 2024)
Therapies targeting mutations in this pathway approved in conjunction with endocrine therapy include alpelisib, everolimus and capivasertib...She received nab-paclitaxel/atezolizumab for 4 months, letrozole and abemaciclib for 2 months, letrozole alone for 6 months, and letrozole and ribociclib for 6 weeks. Given presence of PIK3CA mutation, 4th line treatment with fulvestrant and alpelisib was planned...After progressing on capecitabine after 2 months, alpelisib with exemestane was initiated...Due to a low ejection fraction despite work with cardiooncology, she was not a candidate for trastuzumab deruxtecan. She progressed on oral cyclophosphamide and methotrexate after 2 months and Sacituzumab govitecan after 3 months...Comprehensive biomarker assessment is needed to identify patients who may benefit from sequential therapies. There is a need for trials comparing therapies that target the PI3K pathway at distinct points, potential sequencing of these therapies, and the optimal sequence strategy.
Clinical • PD(L)-1 Biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
|
ER positive • HR positive • PIK3CA mutation • PIK3CA E545K • AKT1 E17K • AKT1 mutation • PIK3CA E545 • PGR negative
|
Guardant360® CDx • MSK-IMPACT
|
Tecentriq (atezolizumab) • everolimus • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Piqray (alpelisib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Kisqali (ribociclib) • fulvestrant • Truqap (capivasertib) • methotrexate • letrozole • Trodelvy (sacituzumab govitecan-hziy) • exemestane
2ms
Clinical Outcomes and the 21-Gene Recurrence Score Assay in Early-Stage Breast Cancer Associated with CHEK2, ATM and PALB2 Germline Pathogenic Variants (SABCS 2024)
Our data demonstrate that higher Oncotype RS, CHEK2 mutations, lymphatic and vascular invasion, and higher Ki67 levels were identified as predictors of poorer RFS. Conversely, older age (>50 years), adjuvant ET, and adjuvant XRT were associated with improved RFS. Importantly, the presence of ATM, CHEK2, or PALB2 mutations did not significantly impact OS.
Clinical • Clinical data
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • ATM (ATM serine/threonine kinase) • PALB2 (Partner and localizer of BRCA2) • CHEK2 (Checkpoint kinase 2)
|
ER positive • HR positive • HER-2 negative • ATM mutation • PALB2 mutation • CHEK2 mutation • HR positive + HER-2 negative • PGR negative • HER-2 negative + ER positive
|
Oncotype DX Breast Recurrence Score®Test
2ms
Multifactor analysis for pathologic complete response (pCR) in a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab (DTP Trial) in HER2-enriched early breast cancer. (SABCS 2024)
While immune markers such as TILs and PD-L1 scores are not typically measured in HER2-positive breast cancers, this data opens up the possibility of rationally leveraging targeted therapies in this subset of immune and HER2-sensitive breast cancers, thus potentially avoiding chemotherapy in the future for this biologically selected group. This regimen holds promise as an effective, relatively non-toxic, and biologically-driven alternative to standard chemotherapy for patients with HER2- enriched subset of early breast cancer.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • ER negative • PGR negative
|
BluePrint • HER2DX
|
Herceptin (trastuzumab) • Imfinzi (durvalumab) • Perjeta (pertuzumab)
2ms
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
HER-2 negative • PGR negative
|
prednisone • dexamethasone • farletuzumab ecteribulin (MORAb-202) • prednisolone
2ms
In vitro fertilization impact on the risk of breast cancer. (PubMed, Arch Clin Cases)
The case involves a 38-year-old patient with a history of hormonally treated endometriosis and five IVF cycles, who presented for mammographic and ultrasound screening. The screening revealed multicentric and multifocal BIRADS-5 lesions, with histopathological and immunohistochemical analysis confirming invasive breast carcinoma of no special type with ductal carcinoma in situ, HER2 positive (3+), estrogen receptor and progesterone receptor negative, and a Ki-67 proliferation index of 50%.
Preclinical • Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • PGR negative
2ms
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis (clinicaltrials.gov)
P2, N=16, Recruiting, Wake Forest University Health Sciences | Trial completion date: Jan 2025 --> Jan 2027 | Trial primary completion date: Oct 2024 --> Mar 2025
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR negative • HER-2 negative + AR positive + ER positive • HER-2 negative + PGR positive
|
methotrexate IV
2ms
Enrollment change • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
HER-2 negative • ER negative • PGR negative
|
INCA33890
2ms
Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor A (VEGF-A) expressions in Ethiopian female breast cancer and their association with histopathologic features. (PubMed, PLoS One)
Epidermal growth factor receptor expression was most likely associated with ER and PR negative tumors. Assessments of multiple molecular markers aid to understand the biological behavior of the disease in Ethiopian population. It might also help to predict which group of patients might get more benefit from the selected treatment strategies and which are not.
Journal
|
EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • PGR (Progesterone receptor) • VEGFA (Vascular endothelial growth factor A)
|
EGFR expression • EGFR overexpression • VEGFA expression • PGR negative
2ms
Study of XB002 in Subjects With Solid Tumors (JEWEL-101) (clinicaltrials.gov)
P1, N=573, Active, not recruiting, Exelixis | Trial completion date: Feb 2025 --> Jul 2025
Trial completion date • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HR positive • HER-2 negative • ER negative • PGR negative
|
Opdivo (nivolumab) • samatatug zovodotin (XB002)
2ms
Frailty and Malnutrition in Surgical Outcomes of Elderly Breast Cancer Patients. (PubMed, J Surg Oncol)
MFI showed a significant predictive value for 5-year survival for patients ≥ 80 and should be part of the preoperative evaluation.
Journal
|
PGR (Progesterone receptor)
|
PGR negative
2ms
Risk factors for second primary breast cancer by laterality, age, and race and ethnicity. (PubMed, J Natl Cancer Inst)
Our findings support genetic risk evaluation, enhanced screening, and lifestyle changes in women at higher risk of SBC. Additional risk factors must contribute to the unequal burden of SBC across racial and ethnic groups.
Journal
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER negative • ER positive + PGR positive • PGR negative
2ms
Breast cancer with cervix, lung and neck metastases: a case report and literature review. (PubMed, AME Case Rep)
We report a relatively rare case of primary breast cancer metastasis to three metastatic sites: cervix, lung, and neck. To our best knowledge, this is the first report of primary breast cancer metastasis to three sites including the cervix.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor) • GATA3 (GATA binding protein 3) • TRPS1 (Transcriptional Repressor GATA Binding 1)
|
HER-2 positive • HER-2 negative • ER negative • PGR negative
3ms
Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer (clinicaltrials.gov)
P2, N=169, Completed, US Oncology Research | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Aug 2024 | Trial primary completion date: Dec 2023 --> Apr 2024
Trial completion • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
albumin-bound paclitaxel • alisertib (MLN8237)
3ms
FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer (clinicaltrials.gov)
P2, N=21, Recruiting, University of Wisconsin, Madison | Suspended --> Recruiting
Enrollment open
|
PGR (Progesterone receptor)
|
PGR negative
3ms
Randomized dose-response trial of n-3 fatty acids in hormone receptor negative breast cancer survivors-impact on breast adipose oxylipin and DNA methylation patterns. (PubMed, medRxiv)
These data provide evidence of both metabolic and epigenetic effects of n-3 PUFAs in breast adipose tissue, elucidating novel mechanisms of action for high-dose EPA+DHA-mediated prevention of ERPR(-) breast cancer. Clinicaltrials.gov identifier NCT02295059.
Journal • Epigenetic controller
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HR negative • PGR negative
3ms
The Predictive Role of Mammography, Dynamic Contrast-Enhanced Breast Magnetic Resonance Imaging and Diffusion-Weighted Imaging in Hormone Receptor Status of Pure Ductal Carcinoma In Situ Lesions. (PubMed, Eur J Breast Health)
Evaluation of DWI findings revealed that a higher lesion-to-normal breast parenchyma apparent diffusion coefficient (ADC) ratio statistically increased the probability of HRc positivity (p = 0.033). Certain clinicopathological, mammography, and MRI features, along with the lesion-to-normal breast parenchyma ADC ratio, can serve as predictors for HRc status in DCIS lesions.
Journal • MRI
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • ER negative • PGR negative
3ms
Her2-positive breast cancer in a young patient with Li-Fraumeni syndrome: A comprehensive case study. (PubMed, Int J Surg Case Rep)
Managing Li-Fraumeni syndrome (LFS) and its associated cancers, particularly in young patients, necessitates a comprehensive and multidisciplinary approach. Early genetic testing for TP53 mutations is crucial in identifying LFS, enabling personalized treatment plans and proactive surveillance strategies.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PGR (Progesterone receptor)
|
HER-2 positive • TP53 mutation • ER-L • PGR negative
|
Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • leuprolide acetate for depot suspension
3ms
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=170, Active, not recruiting, Cyteir Therapeutics, Inc. | Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Jul 2024 --> Dec 2024
Trial completion date • Trial primary completion date
|
ER (Estrogen receptor) • PGR (Progesterone receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
|
HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • MYC translocation • PGR negative • HER-2 negative + AR positive + ER positive • HER-2 negative + PGR positive
|
gemcitabine • Rituxan (rituximab) • capecitabine • bendamustine • CYT-0851
3ms
Trial completion date
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
HER-2 negative • HER-2 expression • PGR negative
|
datopotamab deruxtecan (DS-1062a)
3ms
Knock-out of CD73 delays the onset of HR-negative breast cancer by reprogramming lipid metabolism and is associated with increased tumor mutational burden. (PubMed, Mol Metab)
CD73 has a significant role in tumorigenesis driving the reprogramming of lipid metabolism through the regulatory loop with PR and PPARγ in epithelial cells of mammary glands. Low CD73 expression/CD73 KO might enhance mutational burden by disrupting this regulatory loop, delaying the onset of HR-negative tumors. Our results support combining therapy targeting the CD73-adenosine axis and tumor lipidome against HR-negative tumors, especially at their earliest developmental stage.
Journal • Tumor mutational burden
|
ER (Estrogen receptor) • PGR (Progesterone receptor) • TMB (Tumor Mutational Burden) • MLH1 (MutL homolog 1) • CD73 (5'-Nucleotidase Ecto) • GSTP1 (Glutathione S-transferase pi 1) • NT5E (5'-Nucleotidase Ecto) • PPARG (Peroxisome Proliferator Activated Receptor Gamma)
|
CD73 expression • CD73 underexpression • PGR expression • PGR negative
3ms
CD10 Immunohistochemical Expression in Breast Carcinoma and Its Correlation With Clinicopathological Parameters. (PubMed, Cureus)
A strong association of stromal CD10 expression with a well-established negative prognostic marker such as a higher tumor grade, ER-negative status, and PR-negative status was noted and thus, stromal CD10 expression can be used as an independent prognostic marker in breast carcinoma.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MME (Membrane Metalloendopeptidase)
|
ER negative • PGR negative